Volume 131, Issue 19



May 10, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: How lack of the antioxidant paraoxonase-2 induces a severe prothrombotic state.
See the article by Ebert et al.

Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium
This plenary paper presents a potential mechanism of thrombosis in antiphospholipid syndrome. Using in vitro and in vivo approaches, the investigators obtain detailed insight into the role of the endothelial cell apoER2 receptor complex and downstream signaling in inducing antiphospholipid-induced thrombosis. The study also reveals novel pharmacological targets for antiphospholipid antibody–associated thrombosis.

Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism
This study in patients with antiphospholipid antibodies shows that the risk of recurrent venous thromboembolism significantly increases with the number of positive antibodies.

Paraoxonase-2 regulates coagulation activation through endothelial tissue factor
The authors present a study demonstrating that endothelial cell tissue factor activity induces a severe prothrombotic state in mice lacking the antioxidant paraoxaonase-2.

The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis
This Perspective article highlights recent advances in our understanding of fibrosis-driving events in myelofibrosis and evaluates the role of stromal dysregulation in the initiation and progression of the disease.

Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma
This article presents the first comprehensive profile of both the enhancer landscape and transcriptional network in myeloma.

Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
EZH2 inhibitors are in clinical trials for use in patients with relapsed B-cell lymphomas. This article explores mechanisms by which lymphoma cell lines acquire resistance to small-molecule EZH2 inhibitors.


View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.